Baseline characteristics of patients with and without 1-year MRI erosive progression, and associations between baseline characteristics and MRI erosive progression (univariate logistic regression analyses)
| Comparison of patients with and without MRI erosive progression* | Univariate logistic regression analyses† | ||||
|---|---|---|---|---|---|
| Variables | MRI erosive progression (n=53) | No MRI erosive progression (n=26) | p Value | OR (95% CI) | p Value |
| Demographic variables | |||||
| Female | 38 (71.7) | 23 (88.5) | 0.10 | 3.03 (0.79 to 11.60) | 0.11 |
| Age, years | 57.5 (48.7–65.1) | 58.7 (44.9–68.2) | 0.81 | 1.00 (0.97 to 1.03) | 0.91 |
| Disease duration, days | 112.0 (70.0–190.0) | 91.5 (61.8–192.5) | 0.68 | 1.00 (1.00 to 1.01) | 0.79 |
| Measures of disease severity | |||||
| ESR, mm/h | 15.0 (7.5–25.0) | 12.0 (9.8–22.0) | 0.73 | 1.02 (0.98 to 1.06) | 0.29 |
| CRP, mg/l | 5.2 (2.1–12.3) | 4.4 (1.9–7.6) | 0.25 | 1.04 (0.98 to 1.10) | 0.16 |
| Anti-CCP positive, >25 U/ml | 31 (58.5) | 13 (50.0) | 0.59 | 1.30 (0.50 to 3.38) | 0.59 |
| IgM RF positive, >25 U/ml | 26 (49.1) | 10 (38.5) | 0.45 | 1.44 (0.55 to 3.79) | 0.45 |
| DAS28 | 4.4 (3.0–5.4) | 4.0 (3.3–4.9) | 0.48 | 1.15 (0.80 to 1.64) | 0.46 |
| Imaging modalities | |||||
| MRI synovitis | 5.0 (4.0–6.0) | 4.0 (3.0–6.0) | 0.09 | 1.24 (0.97 to 1.57) | 0.08 |
| MRI BME | 3.0 (1.3–7.0) | 2.0 (1.0–3.0) | 0.05‡ | 1.24 (1.02 to 1.51) | 0.03‡ |
| MRI tenosynovitis | 8.0 (6.0–11.0) | 9.0 (6.0–11.0) | 0.63 | 0.97 (0.85 to 1.11) | 0.66 |
| USGS inflammation | 1.0 (1.0–2.0) | 0.5 (0.0–1.0) | 0.003‡ | 2.15 (1.23 to 3.75) | 0.01‡ |
| DXR BMD, g/m2 | 0.567 (0.506–0.631) | 0.596 (0.502–0.609) | 0.90 | 3.41 (0.01 to 1058.6) | 0.68 |
| DXR BMD, 3-month change, % | −0.4 (−1.3–0.1) | −0.1 (−1.0–0.8) | 0.10 | 0.70 (0.44 to 1.13) | 0.15 |
| Radiographic damage, vdHSS | 2.0 (0.0–6.0) | 2.0 (0.0–4.0) | 0.71 | 1.05 (0.94 to 1.17) | 0.43 |
↵* Median (IQR) for continuous variables, number (%) for counts. Comparison of independent groups by Mann–Whitney U test or χ2 tests.
↵† Dependent variable; MRI erosive progression versus no progression.
↵‡ p Value ≤0.05.
Anti-CCP, antibody to cyclic citrullinated protein; BME, bone marrow oedema; CRP, C-reactive protein; DAS28, disease activity score based on 28 joint count; DXR BMD, digital x-ray radiogrammetry bone mineral density; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; USGS, ultrasound grey-scale; vdHSS, van der Heijde Sharp score.